Data on variant proportions were used by the Food and Drug Administration to recommend inclusion of JN.1 lineages (preferentially KP.2) in updated 2024–2025 COVID-19 vaccines and are expected to guide composition of future vaccines (10). This evidence concerns the gene ERMN and COVID-19.